Association Between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2022 Feb 9

PMID 35135078

Authors

Min Jeong Park

Kyung Mook Choi

Affiliations

Soon will be listed here.

Abstract

Despite strenuous efforts to reduce cardiovascular disease (CVD) risk by improving cardiometabolic risk factors, such as glucose and cholesterol levels, and blood pressure, there is still residual risk even in patients reaching treatment targets. Recently, researchers have begun to focus on the variability of metabolic variables to remove residual risks. Several clinical trials and cohort studies have reported a relationship between the variability of metabolic parameters and CVDs. Herein, we review the literature regarding the effect of metabolic factor variability and CVD risk, and describe possible mechanisms and potential treatment perspectives for reducing cardiometabolic risk factor variability.

Citing Articles

Association between visit-to-visit lipid variability and risk of ischemic heart disease: a cohort study in China.

Wu Y, Shen P, Xu L, Yang Z, Sun Y, Yu L Endocrine. 2023; 84(3):914-923.

PMID: 38159173 DOI: 10.1007/s12020-023-03661-8.

Association between lipid variability and the risk of mortality in cancer patients not receiving lipid-lowering agents.

Kim S, Kim G, Cho S, Oh R, Kim J, Lee Y Front Oncol. 2023; 13:1254339.

PMID: 37869078 PMC: 10586791. DOI: 10.3389/fonc.2023.1254339.

Dose-response relationship between physical activity and cardiometabolic risk in obese children and adolescents: A pre-post quasi-experimental study.

Chen Z, Zhu L Front Physiol. 2023; 14:1070653.

PMID: 36744040 PMC: 9892714. DOI: 10.3389/fphys.2023.1070653.

Long-term variability in physiological measures in relation to mortality and epigenetic aging: prospective studies in the USA and China.

Chen H, Zhou T, Wu S, Cao Y, Zong G, Yuan C BMC Med. 2023; 21(1):20.

PMID: 36647101 PMC: 9843964. DOI: 10.1186/s12916-022-02674-w.

Variability of Metabolic Risk Factors: Causative Factor or Epiphenomenon?.

Yoo H Diabetes Metab J. 2022; 46(2):257-259.

PMID: 35385636 PMC: 8987682. DOI: 10.4093/dmj.2022.0060.

References

Tsuji H, Larson M, Venditti Jr F, Manders E, Evans J, Feldman C . Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996; 94(11):2850-5. DOI: 10.1161/01.cir.94.11.2850. View

Liu T, Pei Y, Peng Y, Chen J, Jiang S, Gong J . Oscillating high glucose enhances oxidative stress and apoptosis in human coronary artery endothelial cells. J Endocrinol Invest. 2014; 37(7):645-51. DOI: 10.1007/s40618-014-0086-5. View

Clement K, Alejo D, DiNatale J, Whitman G, Matthew T, Clement S . Increased glucose variability is associated with atrial fibrillation after coronary artery bypass. J Card Surg. 2019; 34(7):549-554. DOI: 10.1111/jocs.14071. View

Wannamethee G, Ebrahim S, Shaper A . Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol. 1995; 142(7):699-708. DOI: 10.1093/oxfordjournals.aje.a117699. View

Muntner P, Levitan E, Lynch A, Simpson L, Whittle J, Davis B . Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2014; 16(5):323-30. PMC: 4141643. DOI: 10.1111/jch.12290. View

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

Wan E, Yu E, Chin W, Barrett J, Mok A, Lau C . Greater variability in lipid measurements associated with cardiovascular disease and mortality: A 10-year diabetes cohort study. Diabetes Obes Metab. 2020; 22(10):1777-1788. PMC: 7540339. DOI: 10.1111/dom.14093. View

Nusca A, Tuccinardi D, Albano M, Cavallaro C, Ricottini E, Manfrini S . Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes Metab Res Rev. 2018; 34(8):e3047. DOI: 10.1002/dmrr.3047. View

Critchley J, Carey I, Harris T, DeWilde S, Cook D . Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study. Diabetes Care. 2019; 42(12):2237-2246. DOI: 10.2337/dc19-0848. View

10.

Hamm P, SHEKELLE R, Stamler J . Large fluctuations in body weight during young adulthood and twenty-five-year risk of coronary death in men. Am J Epidemiol. 1989; 129(2):312-8. DOI: 10.1093/oxfordjournals.aje.a115135. View

11.

Luo M, Kong X, Wang H, Zhai X, Cai T, Ding B . Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs. J Diabetes Res. 2020; 2020:6666403. PMC: 7707966. DOI: 10.1155/2020/6666403. View

12.

Echouffo-Tcheugui J, Zhao S, Brock G, Matsouaka R, Kline D, Joseph J . Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. Diabetes Care. 2019; 42(3):486-493. PMC: 6463548. DOI: 10.2337/dc18-1430. View

13.

Kim H, Shin J, Lee S, Kim E, Cho J, Son H . A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013; 15(10):810-6. DOI: 10.1089/dia.2013.0038. View

14.

Ntineri A, Kalogeropoulos P, Kyriakoulis K, Aissopou E, Thomopoulou G, Kollias A . Prognostic value of average home blood pressure and variability: 19-year follow-up of the Didima study. J Hypertens. 2017; 36(1):69-76. DOI: 10.1097/HJH.0000000000001497. View

15.

Karlson B, Wiklund O, Palmer M, Nicholls S, Lundman P, Barter P . Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016; 2(4):212-7. DOI: 10.1093/ehjcvp/pvw006. View

16.

Seino Y, Kuwata H, Yabe D . Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. J Diabetes Investig. 2016; 7 Suppl 1:102-9. PMC: 4854513. DOI: 10.1111/jdi.12490. View

17.

Johansson J, Niiranen T, Puukka P, Jula A . Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension. 2012; 59(2):212-8. DOI: 10.1161/HYPERTENSIONAHA.111.178657. View

18.

Costantino S, Paneni F, Battista R, Castello L, Capretti G, Chiandotto S . Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA Levels. Diabetes. 2017; 66(9):2472-2482. DOI: 10.2337/db17-0294. View

19.

Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuodar G . Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis. 2005; 183(2):259-67. DOI: 10.1016/j.atherosclerosis.2005.03.015. View

20.

Myers M, Godwin M, Dawes M, Kiss A, Tobe S, Grant F . Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ. 2011; 342:d286. PMC: 3034423. DOI: 10.1136/bmj.d286. View